All In Biotech

Drugs by condition

Drugs approved for non-small cell lung cancer

Brand-name prescription drugs and biologics whose FDA label lists non-small cell lung cancer as an approved use. Matched on the label phrases: "non-small cell lung cancer", "NSCLC".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

75

Still marketed, NDA or BLA

Drug classes

10

Novel drugs

43

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for non-small cell lung cancer.

  • Jideytro (Zidesamtinib) · Nuvalent NovelOrphanJul 22, 2026
  • Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj) · Janssen Biotech Priority reviewDec 17, 2025
  • Hyrnuo (Sevabertinib) · Bayer Healthcare NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanNov 19, 2025
  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
  • Hernexeos (Zongertinib) · Boehringer Ingelheim NovelBreakthrough therapyAccelerated approvalPriority reviewAug 8, 2025

All approved drugs for non-small cell lung cancer, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 59 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Kinase Inhibitor (14)

  • Hernexeos Zongertinib · Boehringer Ingelheim · 2025
  • Lazcluze Lazertinib Mesylate · Janssen Biotech · 2024
  • Augtyro Repotrectinib · Bristol · 2023
  • Gavreto Pralsetinib · Rigel Pharms · 2020
  • Retevmo Selpercatinib · Eli Lilly and CO · 2020
  • Lorbrena Lorlatinib · Pfizer · 2018
  • Alunbrig Brigatinib · Takeda Pharms USA · 2017
  • Tagrisso Osimertinib Mesylate · Astrazeneca · 2015
  • Gilotrif Afatinib Dimaleate · Boehringer Ingelheim · 2013
  • Xalkori Crizotinib · Pf Prism Cv · 2011
  • Retevmo Selpercatinib · Eli Lilly and CO · 2024
  • Xalkori Crizotinib · Pf Prism Cv · 2023
  • Zykadia Ceritinib · Novartis · 2019
  • Iressa Gefitinib · Astrazeneca · 2015

Vascular Endothelial Growth Factor Inhibitor (6)

  • Avastin Bevacizumab · Genentech · 2004
  • Jobevne Bevacizumab-Nwgd · Biocon Biologics INC · 2025
  • Vegzelma Bevacizumab-Adcd · Celltrion · 2022
  • Alymsys Bevacizumab-Maly · Amneal Pharms LLC · 2022
  • Zirabev Bevacizumab-Bvzr · Pfizer INC · 2019
  • Mvasi Bevacizumab-Awwb · Amgen INC · 2017

Microtubule Inhibitor (6)

Programmed Death Receptor-1 Blocking Antibody (4)

  • Tecentriq Atezolizumab · Genentech INC · 2016
  • Opdivo Nivolumab · Bristol Myers Squibb · 2014
  • Keytruda Pembrolizumab · Merck Sharp Dohme · 2014
  • Tecentriq Hybreza Atezolizumab and Hyaluronidase-Tqjs · Genentech INC · 2024

Endoglycosidase (3)

  • Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
  • Rybrevant Faspro Amivantamab and Hyaluronidase-Lpuj · Janssen Biotech · 2025
  • Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024

CTLA-4-directed Blocking Antibody (2)

  • Imjudo Tremelimumab-Actl · Astrazeneca Ab · 2022
  • Yervoy Ipilimumab · Bristol Myers Squibb · 2011

Programmed Death Ligand-1 Blocker (1)

  • Imfinzi Durvalumab · Astrazeneca Uk LTD · 2017

Vascular Endothelial Growth Factor Receptor 2 Antagonist (1)

  • Cyramza Ramucirumab · Eli Lilly and CO · 2014

Folate Analog Metabolic Inhibitor (1)

  • Axtle Pemetrexed Dipotassium · Avyxa Holdings · 2024

Class not listed in FDA's data (37)

  • Jideytro Zidesamtinib · Nuvalent · 2026
  • Hyrnuo Sevabertinib · Bayer Healthcare · 2025
  • Zegfrovy Sunvozertinib · Dizal · 2025
  • Ibtrozi Taletrectinib Adipate · Nuvation · 2025
  • Emrelis Telisotuzumab Vedotin-Tllv · Abbvie INC · 2025
  • Datroway Datopotamab Deruxtecan-Dlnk · Daiichi Sankyo INC · 2025
  • Ensacove Ensartinib Hydrochloride · Xcovery · 2024
  • Bizengri Zenocutuzumab-Zbco · Merus N.V. · 2024
  • Krazati Adagrasib · Bristol · 2022
  • Lumakras Sotorasib · Amgen INC · 2021
  • Rybrevant Amivantamab-Vmjw · Janssen Biotech · 2021
  • Tepmetko Tepotinib Hydrochloride · Emd Serono INC · 2021
  • Tabrecta Capmatinib Hydrochloride · Novartis Pharm · 2020
  • Enhertu Fam-Trastuzumab Deruxtecan-Nxki · Daiichi Sankyo · 2019
  • Rozlytrek Entrectinib · Genentech INC · 2019
  • Libtayo Cemiplimab-Rwlc · Regeneron Pharmaceuticals · 2018
  • Braftovi Encorafenib · Array Biopharma INC · 2018
  • Mektovi Binimetinib · Array Biopharma INC · 2018
  • Alecensa Alectinib Hydrochloride · Hoffmann-La Roche · 2015
  • Tafinlar Dabrafenib Mesylate · Novartis · 2013
  • Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
  • Alimta Pemetrexed Disodium · Lilly · 2004
  • Taxotere Docetaxel · Sanofi Aventis US · 1996
  • Photofrin Porfimer Sodium · Pinnacle Biolgs · 1995
  • Avgemsi Gemcitabine Hydrochloride · Avyxa Holdings · 2025
  • Rozlytrek Entrectinib · Genentech INC · 2023
  • Pemetrexed Pemetrexed Disodium · Shilpa · 2023
  • Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
  • Tafinlar Dabrafenib Mesylate · Novartis · 2023
  • Docetaxel Docetaxel · Avyxa Holdings · 2022
  • Pemetrexed Disodium Pemetrexed Disodium · Hospira · 2022
  • Pemetrexed Disodium Pemetrexed Disodium · Sandoz · 2022
  • Pemetrexed Pemetrexed · Actavis · 2020
  • Pemfexy Pemetrexed · Eagle Pharms · 2020
  • Docetaxel Docetaxel · Actavis · 2013
  • Gemcitabine Hydrochloride Gemcitabine Hydrochloride · Hospira INC · 2011
  • Docetaxel Docetaxel · Sandoz · 2011

Drugs in development for non-small cell lung cancer

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • AdebrelimabSHR-8068, HRS -4642Phase 341 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • SerplulimabHLX10, HLX43Phase 325 trials

    Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • PF-08634404SSGJ-707Phase 312 trials

    Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)

  • ZimberelimabAB122, GS-0122Phase 312 trials

    Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • Savolitinibhmpl-504, AZD6094Phase 311 trials

    AstraZeneca · Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer

  • TiragolumabMTIG7192A, RO7092284Phase 311 trials

    Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer

  • TQB2102Phase 311 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors

2 discontinued brand-name drugs whose label still names it

More on non-small cell lung cancer: recruiting trials · published research

Related in oncology: Breast cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.